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The Immune System and Chronic Heart Failure
Is the Heart in Control?
James E. Fildes, PHD,*† Steven M. Shaw, MRCP,* Nizar Yonan, MD,*† Simon G. Williams, MD*†
Manchester, United Kingdom
Despite current treatment options, the clinical course of patients with chronic heart failure is notoriously difficult
to predict. Among those with similar etiologies, ejection fractions, and patient demographics, our understanding
of why such variations in outcomes exist remains limited. Evidence that has been progressively gathered impli-
cates an important role of the immune system in the propagation of heart failure. This has been derived mainly
from observations that cytokines are progressively elevated in patients with poor outcomes. However, attempts
at introducing various immunomodulatory therapies as a new treatment strategy have been largely unsuccessful
to date. This possibly reflects a failure in recognizing the complexity of the immune system’s role in chronic
heart failure, which has led to an oversimplified approach to treatment. This review critically analyzes the im-
mune treatments attempted to date and hypothesizes what is required to develop a successful future treatment
strategy. (J Am Coll Cardiol 2009;53:1013–20) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.046h
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collowing reports that serum tumor necrosis factor (TNF)-
lpha concentrations are elevated in patients with severe
hronic heart failure (CHF) (1), an appreciable research
ffort has attempted to describe the role of the immune
ystem in the disease. Many studies have reported elevated
evels of both inflammatory and anti-inflammatory cyto-
ines, together with their corresponding receptors in CHF
2,3). This has led researchers to attempt to address the role
f immune cells in the disease, with many contradictory
ndings (4–6). However, despite an unclear role for the
mmune system in CHF, the utilization of novel immuno-
odulatory treatment modalities has been attempted in
umans, with indifferent results (summarized in Table 1).
ttempts at Immunomodulatory Therapy in CHF
he largest trial of anti–TNF-alpha therapy in humans was
he RENEWAL (Randomized Etanercept Worldwide
valuation) (RENAISSANCE [Randomized Etanercept
orth American Strategy to Study Antagonism of Cyto-
ines] and RECOVER [Research Into Etanercept Cyto-
ine Antagonism in Ventricular Dysfunction]) trial (7).
his international multicenter study of 1,500 heart failure
atients with New York Heart Association (NYHA) func-
ional class II to IV was prematurely terminated as it failed
o demonstrate an advantage of treatment with etanercept (a
ecombinant deoxyribonucleic acid protein that binds to the
rom the *Transplant Centre, University Hospital of South Manchester NHS
oundation Trust, and the †School of Translational Medicine, Faculty of Human and
ife Sciences, University of Manchester, Manchester, United Kingdom.g
Manuscript received August 4, 2008; revised manuscript received October 9, 2008,
ccepted November 2, 2008.uman TNF-alpha receptors via the crystallizable fragment
omponents of immunoglobulin subclass immunoglobulin
1). The study investigators provided 3 putative explana-
ions as to why TNF-alpha inhibition had no clinical benefit
o human heart failure (including the concept that proinflam-
atory cytokines are not involved in CHF, that the dose of
tanercept was not sufficient to adequately inhibit TNF-alpha
unction, or that the “targeted” approach used in this study
ould not disrupt inflammatory processes). Another theory that
ight explain the results of the RENEWAL trial is that
NF-alpha is a pleiotropic cytokine involved in many physi-
logic and pathologic processes, some of which are involved in
ardioprotective pathways. For example, TNF-alpha provides
ndogenous cytoprotective signals that prevent cardiomyocyte
poptosis following ischemic injury (8). Furthermore, the
bsence of TNF type 1 receptors has been associated with
arger myocardial infarction in mice exposed to coronary artery
cclusions (9). In the same models, TNF type 1 receptor
eficiency was also associated with accelerated myocardial
eath (described as an apoptotic or induced process, rather
han necrosis).
The findings of a smaller clinical trial (n 150) using the
himeric monoclonal TNF-alpha antibody, infliximab, in a
ohort of patients with moderate/severe heart failure pro-
ided further evidence of a myocardial requirement for
NF-alpha (10). In this study, patients were grouped as
lacebo (n 49), 5 mg/kg infliximab (n 50), or 10 mg/kg
nfliximab (n  51) and followed up at 14 and 28 weeks.
he investigators reported that patients on high-dose in-
iximab were more likely to experience deterioration in
linical status at both of these time points. Indeed, this
roup was at a higher risk of major adverse events including
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failure and death (hazard ratio:
2.84, p  0.05). Patients were
followed up for a further 5
months following study closure,
and again the investigators re-
ported that the patient group
that had received high-dose in-
fliximab continued to have a
worse clinical outcome than the
other treatment groups. In this
study, both infliximab treatment
groups were associated with a
rapid decrease in serum TNF-
alpha, followed by an increase in
concentration (above baseline
values) at all other time points
over the 28-week study period.
The investigators suggested that
TNF-alpha secretion was in-
creased as a result of antibody
reatment, explaining the poor clinical outcome in the high
ose infliximab group. This would conflict with the concept
hat TNF-alpha is required for myocyte homeostasis and
revention of myocyte death. Yet, this would not explain the
ifference in clinical outcome between the 5-mg/kg versus
0-mg/kg treatment groups. Moreover, the investigators
ould not detect biologically active TNF-alpha in the
amples, suggesting that the elevated TNF-alpha levels were
ctually biologically inactive, TNF-alpha–infliximab com-
lexes. Another theory offered was that infliximab might
otentiate cardiac toxicity of TNF-alpha by forming these
NF-alpha–infliximab complexes, which retain TNF-alpha
n the circulation, prolonging TNF-alpha exposure. This
Abbreviations
and Acronyms
APC  antigen-presenting
cell
CAM  cell adhesion
molecule
CHF  chronic heart failure
DC  dendritic cell
HSP  heat shock protein
IL  interleukin
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
sTNFR  soluble tumor
necrosis factor receptor
TLR  toll-like receptor
TNF  tumor necrosis
factor
ummary of Clinical Trials Attempting the Use of Immunomodulato
Table 1 Summary of Clinical Trials Attempting the Use of Immu
Author (Ref. #) Agent Tar
Mann et al. (7) Etanercept TNF-alpha
Chung et al. (10) Infliximab TNF-alpha
Agoston et al. (13) Thalidomide Multiple modes of
(including TNF-a
Gullestad et al. (14) Thalidomide Multiple modes of
(including TNF-a
Orea-Tejeda et al. (15) Thalidomide Multiple modes of
(including TNF-a
Sliwa et al. (18) Pentoxifylline Multiple modes of
Skudicky et al. (19) Pentoxifylline Multiple modes of
Bahrmann et al. (20) Pentoxifylline Multiple modes of
Pugh et al. (22) Testosterone Suppression of pro
cytokines
Torre-Amione et al. (24) Intragluteal injection apoptotic
autologous blood
Nonspecific immu
Gullestad et al. (33) Octogam (immunoglobulin) Multiple modes of
Aukrust et al. (34) Octogam (immunoglobulin) Multiple modes ofHF  chronic heart failure; LVEF  left ventricular ejection fraction; NYHA  New York Heart Associatiorgument seems “immunologically” flawed because although
e clearly do not understand the positive or negative roles of
NF-alpha in CHF, any effect TNF-alpha may have on the
yocardium will be at the cellular/tissue level, rather than a
irculating, systemic mechanism of action.
Other agents have also been identified as potential
herapeutic tools for CHF because of their capacity to
nhibit TNF-alpha, including the glutamic acid derivative,
halidomide (11). Thalidomide reportedly induces the deg-
adation of TNF-alpha messenger ribonucleic acid tran-
cripts, preventing the accumulation of TNF-alpha messen-
er ribonucleic acid and therefore protein production (12).
wo very small trials (both n  7) and 1 small placebo-
ontrolled study (n  56) (13,14) have reported that
halidomide treatment is associated with an improvement in
eft ventricular ejection fraction (LVEF). However, contrary
o this, a further study of 80 patients with heart failure
eported no effect of thalidomide on LVEF (15). The
ultifarious effects of thalidomide on the immune system
ay explain these contradictory findings. For example,
halidomide inhibits activation of the promoter for the
NF-alpha transcription factor, nuclear factor kappa B, but
nly in monocytes. This has been further defined as thalido-
ide prevents TNF-alpha secretion by monocytes following
ipopolysaccharide stimulation. However, these effects ap-
ear exclusive to monocytic cells and are not replicable in T
ell populations. Indeed, the effects of thalidomide on T
ells appear entirely different. T cells that express the CD4
nd CD8 markers proliferate and secrete inflammatory
ytokines (including interleukin [IL]-2 and interferon-
amma) in response to thalidomide treatment, via costimu-
ation. This costimulatory process has been demonstrated to
nduce TNF-alpha synthesis (in an IL-2–dependent man-
er) by CD4 and CD8 T cells (16). Thalidomide also
ents in the Treatment of CHF
odulatory Agents in the Treatment of CHF
n Outcome (/)
1,500  (study terminated early due to lack of advantage)
150  (infliximab associated with worse outcome)
egradation)
7  (improvement in LVEF)
egradation)
56  (improvement in LVEF)
egradation)
80  (no beneficial effect reported)
28  (improvement in NYHA functional class and LVEF,
decrease in TNF-alpha)
49  (improvement in NYHA functional class and LVEF,
decrease in TNF-alpha)
47  (no improvement in NYHA functional class and
LVEF, decrease in TNF-alpha)
matory 12  (improvement in NYHA functional class)
ulation 2,426 / (primary end point not met, although beneficial
effect reported in NYHA functional class II)
40  (improvement in LVEF)
39  (improvement in LVEF, complement activation)ry Ag
nom
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March 24, 2009:1013–20 The Immune System and CHFnduces the up-regulation of CD40L (CD154) expression
n CD8 T cells, which will protract CD8 T cell lifespan
nd also instigate activation of CD40 dendritic cells
DCs). Thalidomide also has litigious effects on TNF-alpha
n the clinical setting. Several reports have demonstrated a
eduction in serum TNF-alpha concentration following
reatment (7), yet others, including heart failure studies,
ave failed to show any difference or have actually demon-
trated that thalidomide treatment induces an increase in
NF-alpha (14).
Other attempts at therapeutic TNF-alpha modulation
ave also been reported, including treatment with the
anthine derivative pentoxifylline, which exerts peripheral
asodilatory effects, improves blood hemodynamics, and is
eported to reduce serum TNF-alpha (17). The work by
liwa et al. (18) and Skudicky et al. (19) demonstrated that
reatment with pentoxifylline is associated with a significant
mprovement in NYHA functional class and LVEF, along
ith a decrease in circulating TNF-alpha (initially in 28
atients with idiopathic dilated cardiomyopathy) and Fas
described in a follow-up report of 49 patients). However,
he investigators found that alternations to TNF-alpha
oncentration did not directly correlate with LVEF or
YHA functional class improvement and that TNF-alpha
id not represent an independent predictor of outcome in
his small cohort. This suggests that the beneficial effects of
entoxifylline treatment are independent of TNF-alpha,
mplying TNF-alpha depletion is a consequence rather than
cause of cardiac improvement. To add further controversy
o the effects of pentoxifylline, a study by Bahrmann et al.
20) attempted to replicate the Sliwa et al. (18) findings (in
7 patients) without any success. Assessment parameters
ncluded LVEF, NYHA functional class, and biomarker
evels such as B-type natriuretic peptide, IL-6, and TNF-
lpha. The thalidomide and pentoxifylline studies suggest
ur understanding of the immune response in heart failure
equires further explication.
There have also been reports that low levels of androgens
which have been associated with CHF) may be responsible
or increased concentrations of proinflammatory cytokines
such as TNF-alpha) in CHF patients. In vitro studies have
emonstrated that testosterone down-regulates proinflam-
atory cytokine production (including IL-1-beta, IL-6, and
NF-alpha) from a range of cells (reviewed in [21]), and
linical trials using physiological testosterone therapy have
eported improvements in NYHA functional class and
xercise capacity of patients with CHF (22). However,
ecent evidence suggests the in vitro and in vivo data are not
inked. In a placebo-controlled trial (n 94), CHF patients
reated with testosterone when compared with a control
roup were shown to have similar circulating TNF-alpha
oncentrations, suggesting the beneficial effects of testoster-
ne therapy are TNF-alpha–independent (23).
Despite this clear lack of immune understanding, a
linical trial (24) attempted to induce “nonspecific immu-
omodulation” in a cohort of 2,426 patients with NYHA nunctional class II to IV heart failure (24). In this study, the
nvestigators proposed that the intragluteal injection of
utologous blood exposed to stress (ex vivo) would result in
onspecific immunomodulation in patients with CHF and
hereby offer clinical benefits. The results failed to reach
ignificance for the combined primary end point of time to
eath from any cause or first hospitalization for cardiovas-
ular reasons. However, in 2 subgroups of those without
revious myocardial infarction and of those with NYHA
unctional class II CHF, the primary end point was met. It
as therefore suggested that the treatment might have a role
n a large segment of the CHF population. However, the
roposal that CHF patients with NYHA functional class II
eart failure should benefit from immunomodulatory ther-
py above those with more severe grades (III and IV) seems
ounterintuitive. To date, it appears that heightened states
f immune activation correlate with more severe grades of
eart failure (4). If a pathogenic role of the immune system
n this setting is acknowledged, it would seem logical that
hose with more severe NYHA functional classes would
herefore stand to benefit the most. In the ACCLAIM
Advanced Chronic Heart Failure Clinical Assessment of
mmune Modulation Therapy) study, NYHA functional
lass II patients only accounted for 30% and 27% of the
ctive and placebo groups, respectively, which may impact
n the statistical powering behind the otherwise significant
esult. Similar proportions were seen for the other subgroup,
hose with nonischemic CHF, gaining statistical signifi-
ance. More importantly, however, the central tenet behind
his particular study design was immunologically naïve. The
mmune system is a sophisticated and highly regulated
rchestration of cellular and subcellular mechanisms, which
eads to a localized response at a target area. The hypothesis
hat a small volume (10 ml) of autologous, apoptotic
eukocytes injected into the gluteus maximus would system-
cally skew the immune response from inflammatory to
nti-inflammatory seems unlikely. The investigators based
heir theory on in vitro work that reports that the immune
ystem secretes anti-inflammatory cytokines following in-
eraction with apoptotic cells and that apoptosis is the main
orm of myocyte death after coronary occlusion (25). Yet,
ophisticated analysis of cardiomyocytes undergoing cell
eath has demonstrated that apoptosis pathways are not
esponsible, but oncosis, or cell death accompanied by
welling (rather than cell shrinkage seen in apoptosis), could
e (26). Furthermore, apoptosis (which is a routine cellular
vent) occurs between 50 and 70 billion times per day,
ithout any immunomodulatory effects. More specifically to
he immune system, apoptosis acts as a tissue-signaling
echanism. For example, lymphocyte apoptosis occurs
uring propriocidal regulation (27), via TNF-alpha induc-
ion (where TNF-alpha is anchored to the leukocyte sur-
ace, which is then bound by a TNF receptor, inducing a
eath signal) (28), or during passive withdrawal (via IL-2
epletion when antigen is no longer present) (29). These
atural and regulatory forms of apoptosis are not associated
w
i
c
c
T
w
(
e
t
c
t
(
M
t
h
c
i
m
s
s
e
a
r
i
i
(
m
c
(
N
t
(
W
g
T
r
N
q
s
s
L
t
1
i
e
r
u
t
s
m
t
a
a
g
m
i
p
a
l
k
p
s
o
c
k
g
a
t
w
p
i
i
T
g
t
a
s
i
f
e
c
a
e
a
m
I
I
T
s
l
p
h
p
o
T
t
w
l
i
p
r
t
r
i
b
C
c
1016 Fildes et al. JACC Vol. 53, No. 12, 2009
The Immune System and CHF March 24, 2009:1013–20ith a skewed anti-inflammatory response. When stress is
nduced via increased temperature, cells undergo “abnormal”
ell death, rather than programmed cell death. In such
ircumstances, stress proteins are known to up-regulate.
hese include heat shock proteins and heme-1-oxygenase,
hich are known stimulators of antigen-presenting cells
APCs) such as DCs (reviewed in Srivastava [30]). How-
ver, DC responses to such stress proteins are not commit-
ed to anti-inflammatory pathways. Antigen-presenting
ells also recognize intracellular proteins, which upon secre-
ion (following cell death) induce localized, inflammatory
rather than anti-inflammatory) responses (reviewed in
atzinger [31]). Stress protein recognition is not restricted
o APCs. Many innate cells (including natural killer cells)
ave been shown to activate and secrete inflammatory
ytokines following stress protein recognition (23) (the
nvestigators acknowledge reports describing immuno-
odulation of macrophages following heat shock protein
timulation [32]).
These issues are directly applicable to the ACCLAIM
tudy, where cell stress was rapidly induced via ultraviolet
xposure and oxidative stress following treatment with an
nticoagulant. Therefore, the physiological response of the
ecipient immune system to such apoptotic cells is likely to
ncrease inflammatory cytokine production, rather than
mpair it.
Two clinical trials, Gullestad et al. (33) and Aukrust et al.
34), reported beneficial effects of immunoglobulin treat-
ent in patients with CHF and postulated a role for
omplement, and complement therapy. In the first study
33), a cohort of (n 40) chronic, stable CHF patients with
YHA functional class II/III and an LVEF 40% were
reated with a human-derived intravenous immunoglobulin
Octagam, Octopharma Ltd., Roselands, New South
ales, Australia) and compared with a placebo-controlled
roup (n  20) over a 26-week period. Key markers including
NF-alpha, IL-1-beta, IL-10, soluble tumor necrosis factor
eceptor (sTNFR) p55, sTNFR p75, IL-1R-alpha, and
-terminal part of the pro-atrial natriuretic peptide were
uantified, and any change in clinical outcome was de-
cribed. A rise in IL-1R-alpha, IL-10, sTNFR p55, and
TNFR p75 was reported, in addition to an improvement in
VEF (26% to 31%, p  0.001) in the immunoglobulin-
reated group. The changes observed in IL-1R-alpha, IL-
0, sTNFR p55, and sTNFR p75 directly correlated with
mproved EF, suggesting a direct link between these mol-
cules and myocardial function. The investigators also
eported that the N-terminal part of the pro-atrial natri-
retic peptide was decreased following immunoglobulin
reatment, suggesting an improvement in hemodynamic
tatus. As a result, it was concluded that “inflammatory
ediators” are involved in the pathogenesis of CHF. Yet
he mechanisms and immune processes behind these finding
re very interesting and may be of use in identifying novel
pproaches to immunomodulation for CHF. Immuno-
lobulins are multifunctional, interacting with several (echanisms. For example, they are known to prevent
mmune cell–target cell (myocyte) interactions via a series of
rocesses, including crystallizable fragment receptor block-
de and competitive inhibition of antibody-dependent cel-
ular cytotoxicity (35). Furthermore, immunoglobulins are
nown to prevent cell death cascades, which in turn would
revent the expression and/or secretion of endogenous stress
ignals. Endogenous stress signals are essential for activation
f innate cells, including myeloid dendritic cells and mono-
ytes, and effector (target cell killing) cells, including natural
iller cells and macrophages (which will be discussed in
reater detail). In the second study, Aukrust et al. (34), an
ttempt was made to delineate the effect of immunoglobulin
reatment on circulating complement factors in patients
ith CHF (n  39) versus a healthy, untreated control
opulation (n  20). Complement was found to be elevated
n patients with CHF when compared with controls, and
nterestingly, these levels (specifically C3bBbP, C3bc, and
CC) increased further following treatment with immuno-
lobulin. As a result, it was concluded that immunoglobulin
reatment, although beneficial in improving LVEF, was
ssociated with systemic complement activation. However,
ystemic complement activation does not represent an
ncrease in localized complement deposition, so clearly
urther work is required. It would be interesting to study the
ffects of immunoglobulin on the expression of
omplement-activating molecules on the myocyte. For ex-
mple, the expression of CD59 prevents formation of the
ffector molecule of complement (MAC, or the membrane
ttack complex, which binds to the target cell forming
embrane pores).
s the Principle of
mmunomodulation in CHF Wrong?
here has been a great deal of research focused on under-
tanding the role of the immune system in CHF. This has
ed several research groups to attempt clinical trials in
atients with CHF using immunomodulatory therapy that
ave yielded less than encouraging results. However, the
oor outcomes described in these studies may simply reflect
ur lack of understanding of immune processes in CHF.
he frequently published observations demonstrating sys-
emic changes (i.e., elevated type I cytokines) in patients
ith CHF have also been reported in many other patho-
ogical conditions and do not necessarily represent the
mmunologic events that occur at a localized site. In
articular, elevated serum TNF-alpha does not exclusively
epresent systemic immune activation, or a systemic “skew”
oward a Th1 response. Elevated TNF-alpha may be the
esult of a localized secretion at a sight of tissue damage/
mmune activation, which then enters the circulation and
ecomes detectable in blood. The observed increase in
D4 T cells in patients with CHF (4) could represent
ellular activation/motility in response to stress signals
including cytokines) in peripheral blood (CD4 T cells
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March 24, 2009:1013–20 The Immune System and CHFay represent bystander cells in CHF). Clearly, a great deal
f immune characterization is still required to understand
he role and effect of immune activation in CHF. Another
uch ignored, yet potentially viable research avenue is in
nderstanding how the myocardium alerts the immune
ystem following the initial insult that might lead to the
rogressive syndrome of CHF. Indeed, CHF is a common
athway derived from a host of varying etiologies (e.g.,
yocardial ischemia and infarction, hypertension, viral in-
ection, pregnancy, myocarditis), yet the symptomatic, his-
ologic, and immunologic characterization of CHF, irrele-
ant of its cause, appears to be similar. Therefore, it is
ossible that myocardial damage acts as the “adjuvant” to
mmune activation via endogenous signals. This is a key area
f research that the literature appears to be lacking.
HF and Endogenous Stress:
s the Myocardium in Control?
ollowing an initial insult to the myocardium, for example,
coronary plaque rupture with resulting ischemic damage,
ardiac workload is increased as myocytes enter a state of
hyperfunctionality.” Different cellular signaling pathways
ecome activated, augmenting gene transcription and pro-
ein synthesis, which induces myocyte hypertrophy. If this
rocess occurs for a sustained period, cardiac dilation and
ysfunctional contractile motion occur, eventually leading to
ardiac failure. This chronic process is the result of induced
yocyte dysfunction, degeneration, and cell death.
Myocardial damage therefore initiates an immune re-
ponse via the presentation of stress proteins (irrelevant to
he cause of damage, including autoimmune processes that
ead to myocarditis) (Fig. 1). Recent evidence has demon-
trated that myocytes from failing rat hearts have increased
xpression of the endogenous stress protein, heat shock
rotein (HSP)60 (36). This increased expression was re-
orted to occur as a result of mitochondrial damage or
reakdown, a process that results in loss of contractile
unction and cell death. Heat shock protein 60 has also been
mplicated in CHF in humans (37). In this study, HSP60
xpression was doubled in myocytes from patients with
HF compared with controls, yet the protective endoge-
ous signal, HSP72, remained the same. The expression of
SP60 was localized within the myocyte plasma membrane
n the cell surface, and it was also increased in blood plasma.
his increase correlated with increased myocyte death.
SP60 is involved in peptide movement and mitochondrial
unction, but it also represents a ligand for activating
eceptors present on immune cells (toll-like receptors
TLRs]). Therefore, the evolutionary requirement for
SP60 to transfer from the mitochondria to the cell
embrane suggests this protein acts as an endogenous
mmune danger signal. Interestingly, an activating receptor
TLR4) that binds to HSP60 is up-regulated by human
yocytes from patients with heart failure (38). Theoreti-ally, this allows the myocyte to “self-signal”; however, the iignaling cascade that occurs following TLR4-HSP60 liga-
ion in the myocyte is unclear. In general, HSPs represent a
danger signal” for in situ DCs (39). Following HSP
ecognition, DCs activate and migrate to lymph nodes
here they stimulate adaptive immune responses. Interest-
ngly, mitochondrial HSPs may have a protective effect
gainst reactive oxygen species, which induce oxidative
tress to the myocardium, a process that has been well
eported in CHF (reviewed in Grieve and Shah [40]). The
itochondria is known to progressively and chronically
roduce reactive oxygen species (including superoxide and
ydrogen peroxide) in the failing heart (41). This causes the
odulation of calcium-dependent intracellular signaling
ascades that are required for myocardial contraction (42)
nd results in myocyte dysfunction and death. However,
ecent evidence suggests overexpression of mitochondrial
SPs (including HSP10, HSP60, and HSP70) are associ-
ted with cellular survival and prevention of apoptosis
43,44), suggesting that HSP up-regulation in the mito-
hondria might be a survival mechanism, rather than an
ndogenous immune signal (these studies are limited to
schemia reperfusion animal models).
The up-regulation of HSP by the myocardium is therefore
mportant, but not limited to reactions at the plasma mem-
rane. Heat shock proteins are also secreted by damaged or
ecrotic cells (45), where they can mediate potent effects on the
mmune system. For example, HSPs (including HSP60 and
SP90) can act as peptide carriers/transporters and activate
D8 T cells via cross-presentation of antigens (to major
istocompatibility complex class I molecules) (46). Heat shock
roteins activate CD4 T cells and can induce the commit-
ent of naïve (CD45RA CD45RO) T cells (47). Extra-
ellular HSPs can also induce cytokine secretion, including
NF-alpha from APC via ligation with CD14 and TLRs
48). Extracellular HSPs have previously been associated with
range of conditions including atherosclerosis and vascular
isease and are known to be secreted by damaged smooth
uscle cells in vitro. This is clearly an area of importance in the
eart failure setting.
The myocardium can induce positive leukocyte chemo-
axis via the secretion of chemokines (where leukocytes
igrate to the heart in response to increasing concentrations
f chemokines) and also via the expression of chemokine
eceptors (49,50). For example, the chemokine CCL2 is
levated in explanted hearts from patients with CHF (49).
his chemokine binds to its corresponding receptor, CCR2,
n a range of cells including monocytes. Following endo-
ardium CCL2:monocyte CCR2 ligation, monocyte activa-
ion occurs, leading to the production of cytotoxic com-
ounds and reactive oxygen species. This causes endothelial
amage and increased danger signal expression. Further-
ore, endothelial gap junctions become damaged, allowing
he infiltration of leukocytes into the myocardium, where
urther CCR2:CCL2 ligation has been associated with
ncreased myocyte death (51).
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The Immune System and CHF March 24, 2009:1013–20The failing myocardium also provides signals to assist in
eukocyte infiltration, via the up-regulation and/or secretion
f cell adhesion molecules (CAMs). For example, the
ndothelium located in the microvasculature of human
ailing hearts increases the expression of several CAMs,
ncluding P-selectin, e-selectin, intracellular cell adhesion
olecule-1, and vascular cell adhesion molecule-1 (52,53).
his endothelial modification allows the transendothelial
igration of a host of immune cells into the myocardium,
ncluding B cells, T cells, natural killer cells, monocytes,
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March 24, 2009:1013–20 The Immune System and CHForted that the adhesive capacity of peripheral blood mono-
uclear cells directly correlated with the concentration of
irculating CAMs in the patient. This suggests that the
ailing myocardium secretes CAMs, which act as systemic
ctivation signals for circulating cells.
The myocardium further controls its “fate” in response to
tress, via alterations to the death receptor, Fas, following
ell-cell contact with a Fas (ligand) L cell. Fas is a
embrane-bound receptor involved in cell homeostasis.
nder different conditions, Fas binding with FasL induces
ell death. Resting myocytes constitutively express Fas, but
ollowing binding in normal conditions, cell death does not
ccur. However, myocytes exposed to ischemic conditions
eorganize the downstream signaling events following myo-
yte Fas:immune cell FasL binding, so that myocyte death
ccurs (57).
ummary
otentially the myocardium, rather than the immune sys-
em, exerts control over myocyte clearance (via cell death
nd removal). This concept is in keeping with the danger
odel of immunity. The danger model, first postulated by
atzinger (31) states that immune activation occurs in
esponse to damage (or substances that cause damage),
ather than substances that are foreign. The concept origi-
ally applied to pathogenic infections and neoplasia, but
uitably “fits” with our current understanding of disease
rogression and immune involvement in CHF. The multi-
actorial etiologies that cause CHF via myocyte damage lead
o a syndrome with identical disease characteristics. This
ould occur in whole or in part due to loss of self-tolerance
nd the recognition of auto-antigen, via presentation of
ndogenous ligands by the damaged myocardium.
onclusions
vidence suggests that the immune response in heart failure is
secondary phenomenon in response to myocyte injury. If this
roves to be the case, successful treatment of CHF may be
chieved by suppressing stress signals and thus restoring
elf-tolerance to the damaged myocyte. Ultimately, this ap-
roach might prove advantageous in comparison to the recent
ttempts of mere suppression of the immune system.
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